GSK, Adolor stop trials of Entereg over heart risk

04/9/2007 | Age (Melbourne, Australia), The

GlaxoSmithKline and its partner, Adolor Corp., said the drug was designed to treat constipation problems tied to opioid painkillers. But negative findings from a Phase III study found 2.6% of patients treated with Entereg suffered heart problems compared with 1.1% of patients treated with placebos.

View Full Article in:

Age (Melbourne, Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC